{"id":9303,"date":"2024-11-26T11:46:33","date_gmt":"2024-11-26T10:46:33","guid":{"rendered":"https:\/\/www.seventure.fr\/?p=9303"},"modified":"2025-01-09T11:48:03","modified_gmt":"2025-01-09T10:48:03","slug":"maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/","title":{"rendered":"MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,105],"tags":[],"class_list":["post-9303","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-microbiome-nutrition-foodtech-lifestyle"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | Seventure<\/title>\n<meta name=\"description\" content=\"MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in ALS has met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Romane Brunet\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/\",\"url\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/\",\"name\":\"MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2024-11-26T10:46:33+00:00\",\"dateModified\":\"2025-01-09T10:48:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5\"},\"description\":\"MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in ALS has met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5\",\"name\":\"Romane Brunet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"caption\":\"Romane Brunet\"},\"url\":\"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | Seventure","description":"MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in ALS has met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/","twitter_misc":{"Written by":"Romane Brunet"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/","url":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/","name":"MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2024-11-26T10:46:33+00:00","dateModified":"2025-01-09T10:48:03+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"description":"MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in ALS has met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-phase-1b-results-meeting-primary-endpoint-in-the-evaluation-of-maat033-in-amyotrophic-lateral-sclerosis-als\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5","name":"Romane Brunet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","caption":"Romane Brunet"},"url":"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=9303"}],"version-history":[{"count":1,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9303\/revisions"}],"predecessor-version":[{"id":9304,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9303\/revisions\/9304"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=9303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=9303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=9303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}